This bill amends the New Mexico Controlled Substances Act to align the scheduling of crystalline polymorph psilocybin with federal law. Specifically, it introduces a new provision stating that upon the rescheduling of crystalline polymorph psilocybin by the United States Food and Drug Administration, it will be scheduled and listed in accordance with federal regulations. This insertion is found in Section 1, Subsection E, which emphasizes the immediate scheduling of psilocybin to coincide with federal law, including the Controlled Substances Act.

Additionally, the bill modifies Section 30-31-6, which outlines substances included in Schedule I. It adds a new provision (Subsection G) that specifically mentions psilocybin, indicating that it will be included in Schedule I except when it is rescheduled by the FDA. This change reflects a significant shift in the state's approach to psilocybin, recognizing its potential for medical use and aligning state law with evolving federal regulations.

Statutes affected:
introduced version: 30-31-3, 30-31-6